Nexstim NBT® system authorized for commercial distribution in Australia
Press release, Helsinki, 5 August 2019 at 1 pm (EET)
Nexstim NBT ® system authorized for commercial distribution in Australia
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") - the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of major depressive disorder (MDD) - announces that its NBT® system has received a medical device licence from the Health Department of Australian Government.
The medical device licence allows Nexstim to start marketing and selling the NBT ® system for the treatment of major depressive disorder (MDD) in Australia.
The NBT® system uses a unique technology of nTMS known as SmartFocus ® which allows for accurate, reproducible stimulation of the specific area of the brain associated with the treatment of depression.
Martin Jamieson, Chairman and CEO, Nexstim Plc commented: “We are pleased to add Australia as an important market development area for our NBT ® system with SmartFocus ® technology and are looking forward to take the commercialisation further there.”
Further information is available on the website www.nexstim.com or by contacting:
Martin Jamieson, Chairman and CEO
+44 771 516 3942
Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocus® TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company’s proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.
Nexstim’s NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Prosafe SE: First quarter 2020 report – Adapting to a new reality26.5.2020 11:44:38 CEST | Press release
(Figures in brackets refer to the corresponding period of 2019) After several years of low activity across the industry, the company has presented a business plan and a restructuring proposal to lenders which – if approved as proposed – will result in a sustainable balance sheet. The revised business plan reflects a new reality in light of Covid-19, structural changes, oil price collapse, oversupply and anticipated impact on future activity and performance. Consequently, an impairment of USD 810.5 million was made to the book value of vessels in the quarter resulting in a negative book equity of USD 858.9 million by the end of the quarter. The company has sufficient liquidity of USD 184 million at the end of the quarter and continues to operate on a going concern basis on the assumption that there is justified hope to agree a sustainable financial solution with lenders. Recent highlights Prosafe implemented Covid-19 plans early to safeguard people and assets, and this has proven succes
Result of Riksbank reversed auctions SEK Municipal Bonds26.5.2020 11:30:00 CEST | Press release
Result of Riksbank reversed auctions SEK Municipal Bonds Results of auctions Municipal BondsAggregateAuction date5/26/2020Maturity2022Tendered volume, mln SEK750 +/- 750Volume offered, mln SEK1,600Volume bought, mln SEK100Number of bids4Number of accepted bids1Credit Class 1Maturity, QuarterQ1Maturity, QuarterQ2Maturity, QuarterQ3Maturity, QuarterQ4Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume Offered, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Volume bought, mln SEK0Number of bids0Number of bids0Number of bids0Number of bids0Number of accepted bids0Number of accepted bids0Number of accepted bids0Number of accepted bids0Average yield-Average yield-Average yield-Average yield-Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Lowest accepted yield-Highest yield-Highest yield-Highest yield-Highest yield-% accepted at lowest yield-% accepted at lowest yield-% accepted at lowest yield-% accepted at lowest yie
Result of Riksbank certificate sale26.5.2020 10:15:00 CEST | Press release
CERTIFICATE MATURITY200603 FIXED RATE0.00 %OFFERED VOLUME380.000 BLNTOTAL BID AMOUNT1322.350 BLNACCEPTED VOLUME 380.000 BLN PERCENTAGE ALLOTTED 28.7370 %NUMBER OF BIDS14 DEPOSIT RATE-0.10 %LENDING RATE0.20 %
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES MAY 26, 202026.5.2020 09:30:00 CEST | Press release
AUCTION DATE:MAY 26, 2020START DATE:MAY 27, 2020MATURITY DATE:JUN 3, 2020NOMINAL AMOUNT:380.0 BLNFIXED RATE:0.00 % PROJECTED LIQUIDITY SURPLUS FOR THE PERIOD MAY 27 - JUN 3 2020: 738.5 BLN SEK. AT FULL ALLOTMENT EXCESS LIQUIDITY WILL AMOUNT TO APPROXIMATELY 358.5 BLN SEK FOR THE PERIOD MAY 27 - JUN 3 2020. ALL MONETARY POLICY COUNTERPARTIES ARE INVITED TO SUBMIT BIDS TO THE RIKSBANK (08-6966970) BY 10.00 AM ON MAY 26 2020, AT THE LATEST. CONFIRMATION OF BIDS TO E-MAIL: RBCERT@riksbank.se THE LOWEST ACCEPTED BID VOLUME IS SEK 1 MLN. THE HIGHEST ACCEPTED BID VOLUME IS SEK 380.0 BLN. RESULT OF AUCTION WILL BE PUBLISHED AT 10.15 (CEST) ON MAY 26, 2020. COMPLETE TERMS AND CONDITIONS CAN BE RETRIEVED AT WWW.RIKSBANK.SE
ZetaDisplay launches technology partnership with Kastus26.5.2020 09:00:00 CEST | Press release
Malmö –ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) is launching a new partnership with Irish company Kastus® to provide its patented antimicrobial surface-coating technology . The new technology developed by Kastus® and soon to be integrated into the ZetaDisplay product portfolio has proven to be effective against surface bacteria on treated surfaces and can be applied to touchscreens and displays where multiple users will be sharing screens. Independent studies have shown that up to 99.99 per cent of surface bacteria and fungi including antibiotic-resistant superbugs such as MRSA and E. coli were blocked. Chief Commercial Officer of ZetaDisplay Laila Hede Jensen explains: “We are beginning to deploy solutions globally which are enabling retailers, offices and other shared spaces to mitigate risk for the teams and customers using them. A big area of concern are touchscreens and how they are better protected against transmitting surface bacteria. This new partnership enables us to re
ZetaDisplay lanserar teknologi partnerskap med Kastus26.5.2020 09:00:00 CEST | Pressemelding
Malmö –ZetaDisplay AB (publ) (Nasdaq Stockholm: ZETA) lanserar ett nytt partnerskap med det irländska företaget Kastus® för att tillhandahålla dess patenterade antimikrobiella ytbeläggningsteknik. Den nya tekniken som utvecklats av Kastus® och snart kommer att integreras i ZetaDisplays produktportfölj har visat sig vara effektiv mot bakterier på ytor och kan appliceras på pekskärmar och displayer där flera användare kommer att dela dessa. Oberoende studier har visat upp till 99,99 procent av bakterierna och svampar inklusive antibiotikaresistenta superbakterier som MRSA och E. coli blev blockerade på skärmen. Laila Hede Jensen, Chief Commercial Officer för ZetaDisplay, förklarar: "Vi är i startgropen för att distribuera lösningen globalt som gör det möjligt för handeln, kontor och andra offentliga platser att minska riskerna för medarbetare och besökare som använder dessa lokaler. Ett stort problemområde är pekskärmar och hur de kan skyddas bättre mot överföring av bakterier. Detta nya